drugset / Trial / NCT00875394

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

NCT00875394

Phase 3 Completed 68 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy

Timeline

Start
2007-02-01
Primary completion
2008-06-27
Completion
2008-06-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 850 mg
Subject Sitagliptin Small molecule 100 mg